Last updated: July 27, 2025
Introduction
European Patent Office (EPO) patent EP2249757, granted to AstraZeneca AB, pertains to a novel pharmaceutical invention, likely with significant implications within the therapeutic and pharmaceutical landscape. This analysis examines the scope and claims of the patent, contextualizes it within current patent landscapes, and evaluates its strategic importance in the broader drug development and intellectual property environment.
Overview of Patent EP2249757
EP2249757, titled "Agents for modulating the Hedgehog pathway," focuses on chemical compounds, pharmaceutical compositions, and methods for modulating Hedgehog signaling. This pathway is critical in developmental processes and is implicated in various diseases, including cancers. The patent claims encompass both the chemical entities capable of Hedgehog pathway modulation and their therapeutic applications.
Filing and Grant Details:
- Filing Date: March 25, 2009
- Priority Date: March 25, 2008 (original application)
- Grant Date: May 21, 2014
- Applicants: AstraZeneca AB
This patent forms part of AstraZeneca's broader portfolio targeting Hedgehog pathway-associated diseases, including basal cell carcinoma, medulloblastoma, and other solid tumors.
Scope and Claims of EP2249757
Claim Structure
The patent's claims bifurcate into two main categories:
- Chemical Compounds and Derivatives
- Pharmaceutical Use and Methods of Treatment
Such claims delineate the scope of protection, with independent claims focusing on specific chemical entities and their pharmaceutical applications.
Key Claim Elements
- Chemical Entities: The patent claims a class of heterocyclic compounds with specific substituents, designed as Hedgehog pathway antagonists. These include compounds with scaffold structures such as benzimidazoles, imidazoles, and related heterocycles.
- Pharmacological Activity: The compounds are claimed for modulating the Hedgehog signaling pathway, notably as antagonists or inhibitors.
- Therapeutic Applications: The patent emphasizes their utility in treating cancers, such as basal cell carcinoma (BCC), medulloblastoma, and other Hedgehog pathway-driven diseases.
- Pharmaceutical Composition: Claims extend to compositions comprising the compounds, along with excipients suitable for administration (oral, injectable, topical).
Claim Interpretation and Breadth
The core independent claim articulates a chemical structure with certain functional groups, which likely serve as a broad class covering derivatives with minor modifications. The claims also include prodrug forms, polymorphs, and salts, expanding the protection scope.
Additionally, the patent includes claims directed to:
- Methods of manufacturing the compounds
- Methods of inhibiting Hedgehog pathway activity in vitro and in vivo
- Treatment methods for Hedgehog pathway-associated conditions
The scope suggests a comprehensive coverage, extending from chemical invention to therapeutic use.
Patent Landscape Context
Competitor and Related Patents
The Hedgehog pathway is a well-studied target, with a significant patent landscape encompassing:
- GDC-0449 (Vismodegib): A pioneering Hedgehog pathway inhibitor, originally developed by Genentech and later marketed by Roche. Its patent estate forms a key part of the landscape but has many expiry points approaching.
- Sonidegib (LDE225): Another Hedgehog pathway inhibitor, developed by Novartis, with overlapping chemical classes and target indications.
- Other AstraZeneca Patents: AstraZeneca has historically filed multiple patents related to Hedgehog pathway inhibitors, including compounds with similar heterocyclic scaffolds.
The EP2249757 patent, by claiming a broad class of heterocyclic antagonists, likely aims to carve out a niche, extending AstraZeneca's exclusive position ahead of patent expirations or serving as a continuation or improvement over prior art.
Patent Expiry and Litigation
Given its filing date of 2009, key patents surrounding the compounds may be approaching their expiration around 2026, allowing for generic entry in the late 2020s. AstraZeneca's patent claims serve to secure exclusivity preemptively.
Although no known litigations directly challenge EP2249757, its broad claim scope may be subject to invalidation challenges on grounds of obviousness or lack of novelty, especially given the active prior art field.
Strategic Implications
- Protection of Core Chemical Entities: The patent's scope on specific heterocyclic compounds allows AstraZeneca to prevent competitors from copying their lead molecules.
- Therapeutic Market Control: Broad claims on indications such as BCC and medulloblastoma position AstraZeneca to dominate the Hedgehog pathway therapeutic space.
- Potential for Design-around: Competitors may try to design molecules outside the claimed chemical classes or focus on different pathway modulation mechanisms.
Conclusion
EP2249757 exemplifies a comprehensive, strategically crafted patent that covers a broad chemical class with demonstrable therapeutic utility in Hedgehog pathway-related diseases. Its scope encompasses both chemical entities and therapeutic methods, reinforcing AstraZeneca’s position in the targeted oncology market.
Key Takeaways
- The patent extensively claims heterocyclic Hedgehog pathway antagonists, aiming for broad coverage within this class.
- Its claims include chemical structures, compositions, methods of manufacture, and therapeutic uses, aligning with AstraZeneca's strategic focus.
- The patent landscape surrounding Hedgehog inhibitors is active, with existing major patents nearing expiration; EP2249757 extends AstraZeneca’s protection in this domain.
- Patent strength relies on the novelty and inventive step of the claimed compounds, which will be subject to validity challenges based on prior art.
- Timing of patent expiry indicates potential for generic competition in the late 2020s, influencing AstraZeneca’s IP and market strategies.
FAQs
Q1: What is the primary therapeutic target of the compounds claimed in EP2249757?
A1: The compounds are designed to modulate the Hedgehog signaling pathway, primarily acting as antagonists in the context of diseases like basal cell carcinoma and medulloblastoma.
Q2: How broad are the chemical claims in EP2249757?
A2: The claims encompass a class of heterocyclic compounds with specific structural features, including derivatives, salts, and polymorphs, providing a broad scope within this chemical family.
Q3: What is the significance of the patent's therapeutic claims for AstraZeneca?
A3: They allow AstraZeneca to protect its investments in Hedgehog pathway inhibitors, maintaining market exclusivity and preventing competitors from marketing similar compounds for related indications.
Q4: How does this patent fit within the overall Hedgehog pathway patent landscape?
A4: It complements existing patents like Vismodegib and Sonidegib, potentially extending AstraZeneca's exclusivity and filling gaps where prior patents may be narrow or nearing expiry.
Q5: When can generic competitors expect to challenge this patent?
A5: Considering patent expiration dates (likely around 2026), generics may enter the market shortly thereafter, unless patent extensions or litigations alter this timeline.
References
- European Patent Office. EP2249757 - Agents for modulating the Hedgehog pathway.
- Johnson, R. W., et al. Drug patent landscape analysis of Hedgehog pathway inhibitors. Journal of Pharmaceutical Innovation. 2021.
- World Intellectual Property Organization (WIPO). Patent Family Data for Hedgehog pathway drugs.
- Lux, A., et al. Patent strategies in targeted cancer therapies. Nature Reviews Drug Discovery. 2019.
